- Home
- RCUS vs HYT Comparison
RCUS vs HYT Comparison
Compare RCUS & HYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- HYT
- Stock Information
- Founded
- RCUS 2015
- HYT 2003
- Country
- RCUS United States
- HYT United States
- Employees
- RCUS N/A
- HYT N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- HYT Finance Companies
- Sector
- RCUS Health Care
- HYT Finance
- Exchange
- RCUS Nasdaq
- HYT Nasdaq
- Market Cap
- RCUS 1.4B
- HYT 1.4B
- IPO Year
- RCUS 2018
- HYT N/A
- Fundamental
- Price
- RCUS $15.70
- HYT $9.90
- Analyst Decision
- RCUS Strong Buy
- HYT
- Analyst Count
- RCUS 10
- HYT 0
- Target Price
- RCUS $35.88
- HYT N/A
- AVG Volume (30 Days)
- RCUS 611.6K
- HYT 443.0K
- Earning Date
- RCUS 11-05-2024
- HYT 01-01-0001
- Dividend Yield
- RCUS N/A
- HYT 9.61%
- EPS Growth
- RCUS N/A
- HYT N/A
- EPS
- RCUS N/A
- HYT N/A
- Revenue
- RCUS $247,000,000.00
- HYT N/A
- Revenue This Year
- RCUS $132.82
- HYT N/A
- Revenue Next Year
- RCUS N/A
- HYT N/A
- P/E Ratio
- RCUS N/A
- HYT N/A
- Revenue Growth
- RCUS 104.13
- HYT N/A
- 52 Week Low
- RCUS $12.95
- HYT $8.18
- 52 Week High
- RCUS $21.79
- HYT $9.91
- Technical
- Relative Strength Index (RSI)
- RCUS 44.40
- HYT 53.70
- Support Level
- RCUS $15.96
- HYT $9.87
- Resistance Level
- RCUS $17.67
- HYT $10.08
- Average True Range (ATR)
- RCUS 0.90
- HYT 0.08
- MACD
- RCUS -0.20
- HYT 0.00
- Stochastic Oscillator
- RCUS 3.79
- HYT 40.32
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About HYT Blackrock Corporate High Yield Fund Inc.
BlackRock Corporate High Yield Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income and capital appreciation. The trust's secondary investment objective is to provide shareholders with capital appreciation. It seeks to achieve its objectives by investing in a diversified portfolio of fixed-income securities.